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AbstRAct
The cytokine interleukin (IL)−6 performs a diverse 
portfolio of functions in normal physiology and disease. 
These functions extend beyond the typical role for an 
inflammatory cytokine, and IL-6 often displays hormone-
like properties that affect metabolic processes associated 
with lipid metabolism, insulin resistance, and the 
neuroendocrine system. Consequently, the biology of IL-6 
is complex. Recent advances in the field have led to novel 
interpretations of how IL-6 delivers immune homeostasis 
in health and yet drives disease pathology during infection, 
autoimmunity, and cancer. Various biological drugs 
that target IL-6 are in clinical practice or emerging in 
clinical trials and pre-clinical development programmes. 
The challenge is knowing how and when to apply these 
therapies. In this review, we will explore the biology behind 
IL-6 directed therapies and identify some key hurdles for 
future investigation.
A panel of international experts in the field of rheumatology 
recently came together to consider interleukin 6 and its role 
in therapy. 
consideRing the biologicAl pRopeRties 
of il-6
Interleukin 6 (IL-6) is a broad acting cytokine and an 
important therapeutic target for the treatment of diseases 
such as inflammatory rheumatic diseases and some 
cancers. In this regard, IL-6 is characterised by an ability to 
steer the survival, proliferation, and differentiation of cells 
and can direct both pro-inflammatory and anti-inflam-
matory outcomes in infection, autoimmunity, and cancer 
(figure 1).1–3 For example, studies of acute infection show 
that IL-6 controls antimicrobial host defence and prevention 
of excessive tissue injury. However, these same activities 
also promote the progression and maintenance of chronic 
inflammation; IL-6 deficient mice are often protected from 
disease in experimental models of arthritis, lupus, enceph-
alomyelitis, and plasmacytomas. For example, IL-6-defi-
cient mice show limited hallmarks of joint pathology in both 
antigen induced and collagen induced arthritis.4 5 In these 
inflammatory settings, IL-6 controls leucocyte recruitment, 
determines the activity and maintenance of the inflam-
matory infiltrate, and drives various innate and adaptive 
immune responses.1–3 6–8
IL-6 is recognised as a prominent lymphokine that deter-
mines the proliferative survival and effector characteristics 
of T cells and B cells, but it also controls both adaptive and 
innate immunity; in fact, IL-6 plays a role in almost every 
aspect of the innate immune system.1 6 However, perhaps 
more striking is that IL-6 can elicit functions reminiscent 
of a hormone, including effects on the normal homeostatic 
control of vascular function, lipid metabolism, insulin 
resistance, iron transport, mitochondrial activities, the 
neuroendocrine system, and neuropsychological behaviour 
(figure 1).1 9–13 The involvement of IL-6 in these processes is 
reflected by the impact of IL-6-directed therapies on lipid 
biosynthesis and anaemia, as well as effects on patients’ 
well-being including pain, mood, depression, fatigue, and 
sleep (figure 1).8 11 14–17 IL-6 also plays an important role in 
maintaining the functional integrity of tissues and organs 
(such as the liver and mucosal barrier surfaces).18 19 For 
example, IL-6 is involved in maintaining the epithelial 
barrier within the gut, and disruption or blockade of IL-6 
receptor signalling causes a loss of immune homeostasis 
and mucosal integrity.19–21 These findings show the impor-
tance of IL-6 biology at the barrier surface, and they also 
help to explain why a previous history of gastric perfora-
tions or diverticulitis is considered a contraindication for 
therapy with tocilizumab. Thus, when dealing with the 
application of IL-6 targeted interventions it is important to 
reflect on both the contribution of IL-6 to normal physiology 
and its involvement in the underlying pathology.
il-6 signalling
Interleukin six biology is highly complex, and understanding 
how IL-6 receptor signalling can bring about a diverse set of 
biological outcomes is challenging. In this regard, IL-6 has 
been reported to use three distinct forms of receptor signal-
ling—classical IL-6 receptor signalling, IL-6 trans-signal-
ling, and a third recently reported mechanism described as 
IL-6 trans-presentation.1 10 17 22 In the context of this review, 
we will compare the activities associated with classical IL-6 
receptor signalling and IL-6 trans-signalling.
In the classical signalling pathway, IL-6 activates cells by 
first binding a non-signalling α-receptor (IL-6R; CD126), 
which, after dimerisation with β-receptor subunit glycopro-
tein (gp130; also known as CD130), leads to activation of 
receptor associated kinases within the cell, including the 
Janus kinases (Jak1, Jak2) and tyrosine kinase 2 (Tyk2) 
(figure 2) as well as the transcription factors Signal Trans-
ducer and Activator of Transcription (STAT)−1 and STAT3 
that ultimately bind to the respectively responsive genes.9 
All cells in the body express gp130. However, membrane 
associated IL-6R is only present in a very small number of 
cell types—namely, leucocyte subsets, hepatocytes, and 
specialised epithelia, particularly in the gut.1 10 17 23 While 
classical IL-6 receptor signalling controls some important 
inflammatory outcomes (for example, the acute phase 
response and the generation of certain CD4 effector T 
cells), this mode of IL-6 plays a prominent role in the main-
tenance of immune homeostasis.
In contrast, IL-6 trans-signalling is rate limited by the 
presence of a soluble IL-6 receptor (sIL-6R), which forms 
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a complex with IL-6 that structurally resembles heterodimeric cytokines 
such as IL-12, IL-23 and IL-27 (figure 2). For example, sIL-6R shares 60% 
identity with the IL-12p40 subunit.1 In healthy individuals, the concentra-
tion of circulating sIL-6R is 25–35 ng/mL.24 25 However, during disease, 
sIL-6R concentrations may increase by two to threefold, and various 
inflammatory mediators have been shown to promote the active release of 
IL-6R from the surface of neutrophils, monocytic cells, lymphocytes, and 
hepatocytes.1 17 23 26–29
The significance of IL-6 trans-signalling is emphasised by two important 
features. First, the heterodimeric IL-6/sIL-6R complex is an agonist for 
cells expressing gp130 and provides a mechanism to explain how cell 
types that are typically refractory to IL-6 become responsive to IL-6 stim-
ulation. IL-6 trans-signalling, therefore, broadens the types of cells that 
may elicit IL-6 activities—for example, stromal tissue cells including fibro-
blasts, endothelial cells, and smooth muscle cells.1 6 17 23 Second, evidence 
from experimental models increasingly shows that IL-6 trans-signalling 
enhances IL-6 responsiveness and drives inflammatory events.1 10 17 23 
IL-6 trans-signalling is, therefore, considered a primary regulator of IL-6 
biology in local pathology. Characterisation of these activities has signifi-
cantly benefitted from the identification of the soluble gp130 molecule, 
which circulates at high concentrations in healthy individuals (200–400 ng/
mL). This protein antagonises IL-6 activities driven by sIL-6R, leading to 
competitive inhibition of the IL-6/sIL-6R response, and selectively inhibits 
IL-6 trans-signalling in both in vitro and in vivo models.1 17 23 An engineered 
chimeric sgp130 modality is now is in clinical trials as olamkicept.
consideRing the contRibution of il-6 in 
inflAmmAtion
Physiological concentrations of IL-6 are relatively low (1–5 pg/mL) in 
human serum. These concentrations are rapidly elevated in response 
to infection, trauma or injury, and in extreme situations (for example, 
meningococcal septic shock) may reach quantities in the mg/mL range.30 
IL-6 measurements are often better predictors of disease activity than 
assessments of C reactive protein (CRP).1 Elevated concentrations of 
IL-6 are, therefore, an early indicator of infection or inflammation and 
are integral to immunological host defence. Studies in IL-6 deficient 
mice emphasise that IL-6 is required for antimicrobial host immunity.31 
These outcomes occur frequently in humans. For example, children with 
inhibitory autoantibodies to IL-6 often present with recurrent staphylo-
coccal cellulitis and subcutaneous abscesses.32 However, these same 
activities often contribute to the maintenance of chronic inflammation, 
and IL-6 deficient mice show limited hallmarks of pathology in models 
of arthritis, autoimmune encephalomyelitis, lupus, and other inflamma-
tory disorders.1 IL-6 is, therefore, a key orchestrator of pathology, and 
these mouse studies have directly contributed to the successful clinical 
Figure 1 The IL-6 portfolio of functions in normal physiology and disease.
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introduction of tocilizumab and the development of other IL-6 directed 
biological drugs.
How does IL-6 contribute to both local and systemic disease processes? 
First and foremost, IL-6 is characterised as a lymphokine—a cytokine 
that affects the survival, proliferation, differentiation, and effector prop-
erties of T cells and B cells. These properties often help to distinguish 
the biological activity of IL-6 from that of tumour necrosis factor (TNF)-α. 
However, IL-6 is also a potent regulator of innate immune cell activation 
and a primary activator of the hepatic acute phase response (for example, 
CRP, serum amyloid A, fibrinogen, and thrombopoietin).11 18 33 Structural 
cells within the inflamed synovium of patients with rheumatoid arthritis 
typically lack IL-6R expression. These cells express gp130, and regulation 
of IL-6 trans-signalling within the inflamed joint contributes to chemokine 
directed leucocyte recruitment, the retention and activation of the inflam-
matory infiltrate, the transcriptional activation of matrix metalloproteases 
linked cartilage damage, and effects in bone resorption.17 33 For example, 
analysis of synovial fluid from patients with rheumatoid arthritis shows 
an increase in sIL-6R that correlates with leucocyte infiltration and more 
advanced stages of disease activity.34 Mouse models have shown that the 
addition of sgp130 into an inflamed joint significantly reduces the degree 
of inflammation and associated pain, suggesting that IL-6 trans-signalling 
is responsible for driving local disease outcome.34–37
IL-6 receptor signalling promotes activation of the Janus kinase (Jak) 
signal transducers and activators of the transcription (STAT) pathway.9 38 
This pathway has evolved to sense and interpret environmental signals that 
promote cellular growth and functional identity.39 Many of the responses 
attributed to IL-6 are controlled by the latent transcription factors STAT1 
and STAT3 (1, 6, 17, 23). For example, genetic studies in mice show that 
STAT1 and STAT3 activities determine the severity and duration of experi-
mental arthritis.17 36 40 The relevance of the Jak-STAT pathway (and poten-
tially IL-6 biology) to rheumatoid arthritis is perhaps further illustrated by 
genome-wide association studies.41–43 For example, around 20% of gene 
variants predisposing a genetic susceptibility to rheumatoid arthritis are 
linked to IL-6 or the Jak-STAT pathway, either directly in the signalling 
cascade (for example, Tyk2, IL-6ST, IL-6R), through genes transcription-
ally controlled by IL-6 (such as IL-21 and IL-2RB) or responsible for IL-6 
expression (such as IRF5 and IRF8). Computational network analysis of 
genes with genetic risk alleles linked with rheumatoid arthritis identi-
fies STAT1 activity as an important feature of disease development.42 This 
information offers us opportunities to think about the way IL-6 controls 
the pattern of inflammation and its potential contribution to the heteroge-
neity of joint pathology seen clinically.33 A more detailed understanding of 
disease activity will ultimately improve the diagnosis and stratification of 
patients and inform the most appropriate course of therapy.
Although the clinical introduction of tocilizumab as a frontline biological 
drug for the treatment of rheumatoid arthritis illustrates the significance 
of IL-6 in this disease, this therapy has been less impressive in most other 
prevalent autoimmune diseases.1 44 This does not mean that IL-6 does not 
contribute to these diseases. Instead, the failure of IL-6 receptor inhibition 
to improve clinical outcomes in these conditions often reflects the contri-
bution of IL-6 to immune homeostasis and normal tissue physiology.1 33 44 
These clinical observations emphasise the heterogeneity of the inflam-
matory response and imply that the activity of some other cytokines (for 
example, IL-1, IL-17, IL-23, and TNFα) maintains the cytokine network 
at these inflammatory sites.44 Understanding how IL-6 contributes to 
the maintenance of immune homeostasis, yet promotes chronic disease 
progression, will ultimately help to identify how and when IL-6 directed 
interventions may best be applied.
the Role of il-6 in chRonic diseAse pRogRession
Initial studies of cytokine targeted therapies suggested that diseases 
sharing common mechanisms of pathophysiology might respond to a 
variety of biological interventions, but with varying efficacy. Clinical expe-
rience with TNF blockers shows that TNFα inhibition is effective in many 
different diseases including ankylosing spondylitis, juvenile idiopathic 
arthritis, psoriasis, and psoriatic arthritis. However, recent trials show 
that blockade of IL-23 (for ankylosing spondylitis), IL-6 (for juvenile idio-
pathic arthritis), and IL-17 (for psoriasis) may represent viable alternate 
intervention strategies for the treatment of these disorders.3 33 These find-
ings illustrate the context dependent nature of inflammatory reactions and 
support the presence of a cytokine hierarchy that is specific to a defined 
Figure 2 IL-6 classical and trans-signalling pathways.
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disease process.1 3 33 44 In this regard, IL-6 receptor inhibition has shown 
excellent efficacy in rheumatoid arthritis but has had limited success in 
diseases in which IL-6 contributes to epithelial homeostasis or the main-
tenance of barrier integrity.1 20 This is reflected by the adverse incidence 
of gastric perforations and associated diverticulitis as a response to IL-6 
inhibition. The involvement of IL-6 at epithelial barriers is further illus-
trated by its role in antimicrobial host defence.1 17 32 45 Here, clinical trials of 
tocilizumab in atopic dermatitis showed that disruption of IL-6 signalling 
improved the development of skin lesions but caused an adverse incidence 
of bacterial superinfections.45 These outcomes were not unexpected and 
could be predicted on the basis of the biology of IL-6 in viral, parasitic, 
and bacterial infection.1 In this regard, it should be noted that an ances-
tral IL-6-like system in fruit flies promotes innate immunity in response 
to bacterial infection.1 This illustrates the importance of understanding 
fundamental cytokine biology before starting a clinical study.
the cuRRent stAtus of il-6 blocking theRApies
Structure-function studies have provided valuable insight into amino 
acid residues and sequences responsible for IL-6 docking to its cognate 
IL-6R and signal transducing receptor gp130.9 46 47 These interactions are 
complex, and a fully functioning IL-6 receptor consists of a hexameric 
structure involving two molecules of IL-6, two molecules of IL-6R, and two 
molecules of gp130. Ultimately, this has led to the pharmacological design 
of IL-6 directed therapies that prevent IL-6 binding to IL-6R (tocilizumab 
and sarilumab, targeting IL-6R; sirukumab and clazakizumab, targeting 
IL-6), IL-6 engagement with gp130 (olokizumab and EBI-029,targeting 
IL-6), and others that bind unique motifs potentially linked to the regula-
tion of IL-6 trans-signalling (olamkicept—a chimeric engineered sgp130 
protein; NI-1201, targeting IL-6R) (figure 3).1 17 Following a negative review 
from the FDA, sirukimab development and registration has been stopped. 
It should also be noted that Jak inhibitors (such as tofacitinib, ruxolitinib, 
and baricitinib) also inhibit aspects of IL-6 signalling, but these are less 
specific for IL-6 and target other cytokines that use the Jak-STAT pathway 
(figure  3).1 48 49 With the advent of other biological drugs (for example, 
tildrakizumab against IL-23, NNC01140006 against IL-21) and small 
molecule inhibitors (such as Jak inhibitors) that target similar downstream 
signalling pathways to IL-6, differentiating between the modes of action 
of these drugs has become essential. To do this, we must answer the 
following questions: which clinical indications are likely to benefit from IL-6 
inhibition; is there a therapeutic advantage to blocking IL-6 versus IL-6R in 
certain conditions; and can IL-6 trans-signalling be targeted therapeutically 
in human disease, and does this strategy reduce the incidence of contra-
indications potentially associated with classical IL-6 receptor signalling? 
These questions deserve to be considered in two ways. First, the efficacy 
of responses to these drugs needs to be tested across various inflamma-
tory settings using ‘umbrella’ or ‘bucket’ trial designs. Second, similar 
investigations need to be conducted in defined patient groups in which 
an individual disease process may be subdivided into distinct pathotypes 
that reflect differences in local inflammation and responses to therapy. 
In both instances, we need to predict the course of pathology in patients 
whose disease is undifferentiated at presentation and to identify the major 
contributing pathways that drive disease progression in individual patients.
consideRing the biology behind il-6 theRApy—A 
summARy
For a cytokine that was first described more than 30 years ago, it is 
amazing that we continue to acquire new insights into the workings of 
interleukin 6. It signals through a variety of mechanisms, mediates many 
inflammatory processes and homeostatic events, and is tightly regulated 
at the transcriptional (for example, microRNAs, RNA binding proteins, 
circadian control factors) and protein level (for example, IL-6R shedding, 
sgp130 antagonism) through mechanisms that either inhibit or promote 
its action.1 17 The success of IL-6 targeted therapies in certain clinical 
conditions illustrates the prominent role of IL-6 in infection and disease. 
Imitation is often the sincerest form of flattery, and viruses such as human 
herpesvirus eight and human cytomegalovirus have both evolved elegant 
ways to decoy IL-6 responses.50 51 These forms of viral mimicry and adap-
tation contribute to the persona of IL-6 and emphasise its functional 
importance in controlling host immunity.
Figure 3 Therapies directed against IL-6 or IL-6R.
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Pharmaceutical companies and researchers have developed an array 
of new strategies to block this important cytokine. These drugs often 
display unique modes of IL-6 or IL-6R inhibition, and it is hoped that these 
therapies will display unique efficacies in different clinical settings. For 
example, will these alternative interventions limit the development of 
adverse effects associated with IL-6R blockade in some indications? The 
ability to apply approaches and technologies from other clinical special-
ties, such as oncology and genetic screening services, offer opportunities 
to establish how IL-6 sits within a particular cytokine network specific to 
a disease process or pathology. In this regard, we will increasingly see 
the application of systems based methods to obtain a more holistic view 
of drug action in different disease settings.52 Insight derived from these 
approaches will provide valuable bioinformatic datasets and biomarkers 
relevant to the design and interpretation of future clinical trials.
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